Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
Back to Home
C

CTTH

OTC

CTT PHARMACEUTICAL HOLDINGS, INC.

Latest disclosureOctober 6, 2026
Insider score Why 0?
0/ 100
Qualifying buys · 30d
$0

14 purchases · 0 sales

Price by TradingViewDelayed quote from TradingView, for viewing only. It does not power Whale Atlas scores or alerts. If the quote does not load, open the TradingView link.

Insider transactions 14

Limited filing history
All14Buying14Selling0Other0
Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

14 trades · August 7, 2026 – October 6, 2026Incomplete history: this shows the filings imported so far, not every filing ever made. Dates are trade dates. Filters affect this table only.

Showing the first 6 of 14 trades on this page.

Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$203.5
Reported price
$0.055 / share
Traded October 6, 2026Filed October 6, 2026SEC filing
Purchase disclosedAmended filing

Ctt Pharmaceutical Holdings

CEO

Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$454.5
Reported price
$0.045 / share
Traded September 22, 2026Filed September 29, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$187
Reported price
$0.055 / share
Traded September 28, 2026Filed September 28, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
Unavailable
Reported price
$0.045 / share
Traded September 22, 2026Filed September 22, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$523.2
Reported price
$0.048 / share
Traded September 16, 2026Filed September 16, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$175
Reported price
$0.05 / share
Traded September 10, 2026Filed September 10, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$479.22
Reported price
$0.0489 / share
Traded September 4, 2026Filed September 4, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$146.7
Reported price
$0.0489 / share
Traded September 2, 2026Filed September 2, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$171.5
Reported price
$0.049 / share
Traded August 31, 2026Filed August 31, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$115.5
Reported price
$0.055 / share
Traded August 24, 2026Filed August 24, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$517.5
Reported price
$0.045 / share
Traded August 20, 2026Filed August 20, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$590
Reported price
$0.059 / share
Traded August 19, 2026Filed August 19, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$111.6
Reported price
$0.062 / share
Traded August 14, 2026Filed August 14, 2026SEC filing
Purchase disclosed

Ctt Pharmaceutical Holdings

CEO

CTTH

Excluded from the common-share buying signal. See trade details.

Reported value
$500.5
Reported price
$0.065 / share
Traded August 7, 2026Filed August 10, 2026SEC filing
Reporting insiderSecurity / transactionAmount / priceValueTraded / disclosedSource
CEOCTTHPurchaseExcluded from purchase score3,700$0.06 / share$203.5Oct 6Filed Oct 6 · 0d laterSEC filing
CEO
Amended

Related filings are retained as evidence. This economic transaction is counted once.

This amendment supersedes the related original transaction.

Original SEC filing ↗Amended SEC filing ↗
CTTHPurchaseExcluded from purchase score10,100$0.05 / share$454.5Sep 22Filed Sep 29 · 7d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score3,400$0.06 / share$187Sep 28Filed Sep 28 · 0d laterSEC filing
CEO
Superseded by later filing

Related filings are retained as evidence. This economic transaction is counted once.

This original record remains available as evidence. The later filing replaces it in totals and buying signals.

Superseding SEC filing ↗Original transaction filing ↗
CTTHPurchaseExcluded from purchase score10,100$0.05 / shareUnavailableSep 22Filed Sep 22 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score10,900$0.05 / share$523.2Sep 16Filed Sep 16 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score3,500$0.05 / share$175Sep 10Filed Sep 10 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score9,800$0.05 / share$479.22Sep 4Filed Sep 4 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score3,000$0.05 / share$146.7Sep 2Filed Sep 2 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score3,500$0.05 / share$171.5Aug 31Filed Aug 31 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score2,100$0.06 / share$115.5Aug 24Filed Aug 24 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score11,500$0.05 / share$517.5Aug 20Filed Aug 20 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score10,000$0.06 / share$590Aug 19Filed Aug 19 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score1,800$0.06 / share$111.6Aug 14Filed Aug 14 · 0d laterSEC filing
CEOCTTHPurchaseExcluded from purchase score7,700$0.07 / share$500.5Aug 7Filed Aug 10 · 3d laterSEC filing
Explore furtherTechnical lab Company financials Test a strategy Compare company

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Source
SEC EDGAR · Form 4
Issuer CIK
0001035422
Latest public acceptance
Oct 6, 2026, 09:24 PM UTC
Score calculated
Oct 7, 2026, 12:06 AM UTC
Parser
form4-parser-1.5
Classifier
form4-classifier-1.1
Scoring methodology
insider-experimental-1.1
Availability
Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Congress transactions 0

All Congress filings
No disclosed congressional trades for CTTH in the imported filings.

This reflects the filings imported so far, not a complete trading history.

Limited filing history · Market-wide discovery does not establish complete company history. View coverage